

Supplementary Table S1. Characteristics of *ex vivo* treated ovarian ascites samples used in this study.

ID	DECIDER ID	Ovarian cancer histology	Treatment before ascites collection	MX1 ↑	scRNA-seq batch
1	EOC123	Mucinous	No	R	2
2	EOC402	High grade serous	No	NoR	
3	EOC340	High grade serous	No	R	
4	EOC1038	High grade serous	No	NoR	
5	EOC268	High grade serous	No	NoR	
6	EOC864	High grade serous	No	NoR	2*
7	EOC357	High grade serous	No	NoR	
8	EOC551	High grade serous	No	NoR	2
9	EOC1002	High grade serous	No	NoR	1
10	EOC126	High grade serous	No	NoR	1
11	EOC737	High grade serous	Yes, residue sample**	R	2
12	EOC725	Low grade serous	No	R	1
13	EOC984	High grade serous	No	NoR	
14	EOC523	High grade serous	No	R	1

* excluded from scRNA-seq analyses due to poor scRNA-seq data quality

**6 cycles of carboplatin+paclitaxel two years earlier, one dose of carboplatin+paclitaxel 24h before ascites collection